Search research articles
Contact Us
Filters
Showing results (21-30 of 171) with videos related to
Page
of 18
Sort By:
Drug Safety
|
January 14, 2020
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Hans-Christian Kolberg, Marco Colleoni, Georgia Savva Demetriou, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 18, 2021
Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events
Fränce Hardtstock, Zeki Kocaata, Thomas Wilke, et al.
Onkologie
|
April 4, 2013
[Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials]
Kristina Ihrig, Birgit Fath, Michael Fuchs, et al.
Journal of Gastrointestinal Cancer
|
June 26, 2025
Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer
Karin Potthoff, Norbert Marschner, Lothar Müller, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 2, 2013
Clinical experience with Zarzio® in Europe: what have we learned?
Pere Gascón, Hans Tesch, Karl Verpoort, et al.
Annals of Hematology
|
June 25, 2010
Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective
Felicitas Kühne, Thomas Mittendorf, Ulrich Germing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2021
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study
Diana Lüftner, Hans Tesch, Marcus Schmidt, et al.
BMC Cancer
|
December 10, 2014
Trastuzumab in advanced breast cancer--a decade of experience in Germany
Christian Jackisch, Winfried Schoenegg, Dietmar Reichert, et al.
British Journal of Haematology
|
November 20, 2002
An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591
Martina Vockerodt, Gazanfer Belge, Dieter Kube, et al.
Oncology Research and Treatment
|
August 4, 2016
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload
Harald-Robert Bruch, Yves Dencausse, Jörg Heßling, et al.
Page
of 18
Search research articles
Search
Showing results (21-30 of 171) with videos related to
Sort By:
Page
of 18
Drug Safety
|
January 14, 2020
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Hans-Christian Kolberg, Marco Colleoni, Georgia Savva Demetriou, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 18, 2021
Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events
Fränce Hardtstock, Zeki Kocaata, Thomas Wilke, et al.
Onkologie
|
April 4, 2013
[Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials]
Kristina Ihrig, Birgit Fath, Michael Fuchs, et al.
Journal of Gastrointestinal Cancer
|
June 26, 2025
Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer
Karin Potthoff, Norbert Marschner, Lothar Müller, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 2, 2013
Clinical experience with Zarzio® in Europe: what have we learned?
Pere Gascón, Hans Tesch, Karl Verpoort, et al.
Annals of Hematology
|
June 25, 2010
Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective
Felicitas Kühne, Thomas Mittendorf, Ulrich Germing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2021
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study
Diana Lüftner, Hans Tesch, Marcus Schmidt, et al.
BMC Cancer
|
December 10, 2014
Trastuzumab in advanced breast cancer--a decade of experience in Germany
Christian Jackisch, Winfried Schoenegg, Dietmar Reichert, et al.
British Journal of Haematology
|
November 20, 2002
An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591
Martina Vockerodt, Gazanfer Belge, Dieter Kube, et al.
Oncology Research and Treatment
|
August 4, 2016
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload
Harald-Robert Bruch, Yves Dencausse, Jörg Heßling, et al.
Page
of 18